Arrowstreet Capital Limited Partnership Sells 114,947 Shares of Phibro Animal Health Corporation $PAHC

Key Points

• Arrowstreet Capital cut its Phibro Animal Health stake by 57% in the first quarter, selling 114,947 shares and retaining 86,782 shares valued at approximately $4.8 million. Institutional investors and hedge funds collectively own 99.34% of the company.
• Analyst sentiment has weakened, with several firms downgrading the stock and Citigroup reducing its price target to $44. The consensus rating is “Hold”, with an average target price of $42.50.
• Phibro reported quarterly EPS of $0.76, beating estimates of $0.72, on revenue of $383.54 million. The company also declared a quarterly dividend of $0.12, equivalent to a 1.3% annualized yield.

Arrowstreet Capital Limited Partnership lowered its holdings in Phibro Animal Health Corporation (NASDAQ:PAHC - Free Report) by 57.0% during the first quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 86,782 shares of the company's stock after selling 114,947 shares during the quarter. Arrowstreet Capital Limited Partnership owned 0.21% of Phibro Animal Health worth $4,800,000 at the end of the most recent quarter.

A number of other large investors also recently modified their holdings of the business. Sei Investments Co. grew its stake in shares of Phibro Animal Health by 15.7% in the first quarter. Sei Investments Co. now owns 156,948 shares of the company's stock worth $8,681,000 after acquiring an additional 21,339 shares during the last quarter. Cetera Investment Advisers grew its position in Phibro Animal Health by 2.7% in the 1st quarter. Cetera Investment Advisers now owns 10,997 shares of the company's stock worth $608,000 after purchasing an additional 293 shares during the last quarter. Dimensional Fund Advisors LP increased its holdings in shares of Phibro Animal Health by 3.2% during the 1st quarter. Dimensional Fund Advisors LP now owns 507,852 shares of the company's stock worth $28,086,000 after purchasing an additional 15,517 shares during the period. KBC Group NV acquired a new position in shares of Phibro Animal Health during the first quarter valued at about $29,000. Finally, Allspring Global Investments Holdings LLC lifted its stake in shares of Phibro Animal Health by 145.5% in the first quarter. Allspring Global Investments Holdings LLC now owns 286,172 shares of the company's stock valued at $15,671,000 after buying an additional 169,628 shares during the period. 99.34% of the stock is currently owned by institutional investors and hedge funds.

Analyst Ratings Changes

Several equities analysts have commented on PAHC shares. Weiss Ratings cut Phibro Animal Health from a "buy (b-)" rating to a "hold (c+)" rating in a report on Monday, June 15th. Zacks Research lowered Phibro Animal Health from a "strong-buy" rating to a "hold" rating in a research note on Thursday, May 21st. Wall Street Zen lowered shares of Phibro Animal Health from a "strong-buy" rating to a "buy" rating in a report on Saturday, May 9th. Finally, Citigroup reduced their price objective on shares of Phibro Animal Health from $62.00 to $44.00 and set a "neutral" rating for the company in a report on Thursday, May 14th. One investment analyst has rated the stock with a Buy rating, three have assigned a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat, the company currently has a consensus rating of "Hold" and an average target price of $42.50.

Insiders Place Their Bets

In related news, CEO Jack Bendheim sold 4,528 shares of the business's stock in a transaction that occurred on Thursday, May 7th. The shares were sold at an average price of $48.49, for a total value of $219,562.72. Following the completion of the transaction, the chief executive officer owned 56,152 shares in the company, valued at $2,722,810.48. The trade was a 7.46% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 50.13% of the stock is owned by company insiders.

Phibro Animal Health Stock Up 2.3%

Shares of NASDAQ:PAHC opened at $37.15 on Tuesday. Phibro Animal Health Corporation has a 12 month low of $26.08 and a 12 month high of $60.08. The company's 50-day moving average price is $32.78 and its two-hundred day moving average price is $43.15. The company has a quick ratio of 1.26, a current ratio of 3.17 and a debt-to-equity ratio of 1.97. The firm has a market cap of $1.51 billion, a P/E ratio of 15.94, a P/E/G ratio of 0.51 and a beta of 0.46.

Phibro Animal Health (NASDAQ:PAHC - Get Free Report) last posted its quarterly earnings data on Wednesday, May 6th. The company reported $0.76 earnings per share for the quarter, beating the consensus estimate of $0.72 by $0.04. Phibro Animal Health had a net margin of 6.35% and a return on equity of 37.14%. The firm had revenue of $383.54 million during the quarter, compared to analysts' expectations of $367.02 million. Phibro Animal Health has set its FY 2026 guidance at 2.980-3.100 EPS. As a group, research analysts forecast that Phibro Animal Health Corporation will post 3.08 EPS for the current fiscal year.

Phibro Animal Health Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Wednesday, September 23rd. Investors of record on Wednesday, September 2nd will be issued a $0.12 dividend. The ex-dividend date of this dividend is Wednesday, September 2nd. This represents a $0.48 dividend on an annualized basis and a dividend yield of 1.3%. Phibro Animal Health's dividend payout ratio (DPR) is currently 20.60%.

About Phibro Animal Health

Phibro Animal Health Corporation NASDAQ: PAHC is a diversified global animal health and mineral nutrition company headquartered in Teaneck, New Jersey. The company develops, manufactures and markets a broad range of pharmaceutical, mineral nutrition and performance products designed to support the health and productivity of livestock, companion animals and aquaculture species. Phibro's portfolio includes vaccines, anti-infective therapies, coccidiostats, disinfectants, premix minerals and specialty feed additives aimed at enhancing growth, immunity and overall animal well-being.

The company operates through three principal business segments: Animal Health, Mineral Nutrition and Performance Products.

Want to see what other hedge funds are holding PAHC? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Phibro Animal Health Corporation (NASDAQ:PAHC - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source